原发性甲状旁腺功能亢进症
手术指征同散发性甲状旁腺功能亢进症，对明显增大的甲状旁腺应该被切除。如果4 个腺体均增大，应该次全切除甲状旁腺，即在原位部分保留一个带有血管蒂腺体，或者甲状旁腺全切同时将一个腺体部分异位移植。手术无法治愈或无法耐受手术的患者，可使用钙敏感受体促进剂如西那卡塞（Cinacalcet）。
参考文献
[1] Nilsson M, Williams D.On the Origin of Cells and Derivation of Thyroid Cancer: C Cell Story Revisited[J].Eur Thyroid J,2016,5(2):79-93.
[2] Le Douarin N M, Dupin E.Cell lineage analysis in neural crest ontogeny[J].J Neurobiol,1993,24(2):146-161.
[3] Kameda Y, Nishimaki T, Chisaka O, et al.Expression of the epithelial marker E-cadherin by thyroid C cells and their precursors during murine development[J].J Histochem Cytochem,2007,55(10):1075-1088.
[4] Schmid K W.Histopathology of C Cells and Medullary Thyroid Carcinoma[J].Recent Results Cancer Res,2015,204:41-60.
[5] Leboeuf R, Langlois M F, Martin M, et al.“Hook effect”in calcitonin immunoradiometric assay in patients with metastatic medullary thyroid carcinoma: case report and review of the literature[J].J Clin Endocrinol Metab,2006,91(2):361-364.
[6] D’Herbomez M, Caron P, Bauters C, et al.Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking[J].Eur J Endocrinol,2007,157(6):749-755.
[7] Basuyau J P, Mallet E, Leroy M, et al.Reference intervals for serum calcitonin in men, women, and children[J].Clin Chem,2004,50(10):1828-1830.
[8] Muller B, White J C, Nylen E S, et al.Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis[J].J Clin Endocrinol Metab,2001,86(1):396-404.
[9] Graze K, Spiler I J, Tashjian A J, et al.Natural history of familial medullary thyroid carcinoma: effect of a program for early diagnosis[J].N Engl J Med,1978,299(18):980-985.
[10] Freichel M, Zink-Lorenz A, Holloschi A, et al.Expression of a calcium-sensing receptor in a human medullary thyroid carcinoma cell line and its contribution to calcitonin secretion[J].Endocrinology,1996,137(9):3842-3848.
[11] Aloia J F, Rasulo P, Deftos L J, et al.Exercise-induced hypercalcemia and the calciotropic hormones[J].J Lab Clin Med,1985,106(3):229-232.
[12] Dymling J F, Ljungberg O, Hillyard C J, et al.Whisky:a new provacative test for calcitonin secretion[J].Acta Endocrinol (Copenh),1976,82(3):500-509.
[13] Cooper C W, Schwesinger W H, Mahgoub A M,et al.Thyrocalcitonin: stimulation of secretion by pentagastrin[J].Science,1971,172(3989):1238-1240.
[14] Endo T, Saito T, Uchida T, et al.Effects of somatostatin and serotonin on calcitonin secretion from cultured rat parafollicular cells[J].Acta Endocrinol(Copenh),1988,117(2):214-218.
[15] Bell N H.Effects of glucagon, dibutyryl cyclic 3',5'-adenosine monophosphate, and theophylline on calcitonin secretion in vitro[J].J Clin Invest,1970,49(7):1368-1373.
[16] Bjerre K L, Madsen L W, Andersen S, et al.Glucagonlike Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation[J].Endocrinology,2010,151(4):1473-1486.
[17] Trimboli P, Giovanella L, Crescenzi A, et al.Medullary thyroid cancer diagnosis: an appraisal[J].Head Neck,2014,36(8):1216-1223.
[18] Mian C, Perrino M, Colombo C, et al.Refining calcium test for the diagnosis of medullary thyroid cancer:cutoffs, procedures, and safety[J].J Clin Endocrinol Metab,2014,99(5):1656-1664.
[19] Hoff A O, Catala-Lehnen P, Thomas P M, et al.Increased bone mass is an unexpected phenotype associated with deletion of the calcitonin gene[J].J Clin Invest,2002,110(12):1849-1857.
[20] Dacquin R, Davey R A, Laplace C, et al.Amylin inhibits bone resorption while the calcitonin receptor controls bone formation in vivo[J].J Cell Biol,2004,164(4):509-514.
[21] Scheuba C, Kaserer K, Kotzmann H, et al.Prevalence of C-cell hyperplasia in patients with normal basal and pentagastrin-stimulated calcitonin[J].Thyroid,2000,10(5):413-416.
[22] Baschieri L, Castagna M, Fierabracci A, et al.Distribution of calcitonin- and somatostatin-containing cells in thyroid lymphoma and in Hashimoto’s thyroiditis[J].Appl Pathol,1989,7(2):99-104.
[23] Kaserer K, Scheuba C, Neuhold N, et al.C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin[J].Am J Surg Pathol,1998,22(6):722-728.
[24] Ting S, Synoracki S, Schmid K W.Thyroid C cells and their pathology: Part 1: normal C cells, - C cell hyperplasia, - precursor of familial medullary thyroid carcinoma[J].Pathologe,2015,36(3):246-253.
[25] Sheu S Y, Schmid K W.Multiple endocrine neoplasia type 2[J].Pathologe,2010,31(6):449-454.
[26] Schmid K W, Ensinger C.“Atypical”medullary thyroid carcinoma with little or no calcitonin expression[J].Virchows Arch,1998,433(3):209-215.(https://www.daowen.com)
[27] Frank-Raue K, Machens A, Leidig-Bruckner G, et al.Prevalence and clinical spectrum of nonsecretory medullary thyroid carcinoma in a series of 839 patients with sporadic medullary thyroid carcinoma[J].Thyroid,2013,23(3):294-300.
[28] Smallridge R C, Ain K B, Asa S L, et al.American Thyroid Association guidelines for management of patients with anaplastic thyroid cancer[J].Thyroid: official journal of the American Thyroid Association,2012,22(11):1104-1139.
[29] Wolfe H J, Delellis R A.Familial medullary thyroid carcinoma and C cell hyperplasia[J].Clin Endocrinol Metab,1981,10(2):351-365.
[30] Kiefer I, Odermatt D, Anneville O, et al.Application of remote sensing for the optimization of in-situ sampling for monitoring of phytoplankton abundance in a large lake[J].Sci Total Environ,2015,527-528.
[31] Mulligan L M, Kwok J B, Healey C S, et al.Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A[J].Nature,1993,363(6428):458-460.
[32] Komminoth P, Roth J, Muletta-Feurer S, et al.RET protooncogene point mutations in sporadic neuroendocrine tumors[J].J Clin Endocrinol Metab,1996,81(6):2041-2046.
[33] Zedenius J, Larsson C, Bergholm U, et al.Mutations of codon 918 in the RET proto-oncogene correlate to poor prognosis in sporadic medullary thyroid carcinomas[J].J Clin Endocrinol Metab,1995,80(10):3088-3090.
[34] Schilling T, Burck J, Sinn H P, et al.Prognostic value of codon 918 (ATG→ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma[J].Int J Cancer,2001,95(1):62-66.
[35] Asai N, Iwashita T, Matsuyama M, et al.Mechanism of activation of the ret proto-oncogene by multiple endocrine neoplasia 2A mutations[J].Mol Cell Biol,1995,15(3):1613-1619.
[36] Santoro M, Carlomagno F, Romano A, et al.Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B[J].Science,1995,267(5196):381-383.
[37] Asai N, Iwashita T, Murakami H, et al.Mechanism of Ret activation by a mutation at aspartic acid 631 identified in sporadic pheochromocytoma[J].Biochem Biophys Res Commun,1999,255(3):587-590.
[38] Ohiwa M, Murakami H, Iwashita T, et al.Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations[J].Biochem Biophys Res Commun,1997,237(3):747-751.
[39] Gujral T S, Singh V K, Jia Z, et al.Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2B[J].Cancer Res,2006,66(22):10741-10749.
[40] Cranston A, Carniti C, Martin S, et al.A novel activating mutation in the RET tyrosine kinase domain mediates neoplastic transformation[J].Mol Endocrinol,2006,20(7):1633-1643.
[41] Plaza M I, Koster R, van der Sloot A M, et al.RETfamilial medullary thyroid carcinoma mutants Y791F and S891A activate a Src/JAK/STAT3 pathway, independent of glial cell line-derived neurotrophic factor[J].Cancer Res,2005,65(5):1729-1737.
[42] Segouffin-Cariou C, Billaud M.Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway[J].J Biol Chem,2000,275(5):3568-3576.
[43] De Vita G, Melillo R M, Carlomagno F, et al.Tyrosine 1062 of RET-MEN2A mediates activation of Akt(protein kinase B) and mitogen-activated protein kinase pathways leading to PC12 cell survival[J].Cancer Res,2000,60(14):3727-3731.
[44] Kebebew E, Ituarte P H, Siperstein A E, et al.Medullary thyroid carcinoma: clinical characteristics, treatment,prognostic factors, and a comparison of staging systems[J].Cancer,2000,88(5):1139-1148.
[45] Wells S J, Asa S L, Dralle H, et al.Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma[J].Thyroid,2015,25(6):567-610.
[46] Pacini F, Castagna M G, Cipri C, et al.Medullary thyroid carcinoma[J].Clin Oncol (R Coll Radiol),2010,22(6):475-485.
[47] Gharib H, Papini E, Garber J R, et al.American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical guidelines for the diagnosis and management of thyroid nodules-2016 update [J].Endocr Pract, 2016,22(5):622-639.
[48] Leenhardt L, Erdogan M F, Hegedus L, et al.European thyroid association guidelines for cervical ultrasound scan and ultrasound-guided techniques in the postoperative management of patients with thyroid cancer[J].European thyroid journal,2013;2(3):147-159.
[49] Perros P, Boelaert K, Colley S, et al.Guidelines for the management of thyroid cancer[J].Clin Endocrinol(Oxf),2014,81 Suppl 1:1-122.
[50] Brandi M L, Gagel R F, Angeli A, et al.Guidelines for diagnosis and therapy of MEN type 1 and type 2[J].J Clin Endocrinol Metab,2001,86(12):5658-5671.
[51] Yeh M W, Bauer A J, Bernet V A, et al.American Thyroid Association statement on preoperative imaging for thyroid cancer surgery[J].Thyroid,2015,25(1):3-14.
[52] Shindo M L, Caruana S M, Kandil E, et al.Management of invasive well-differentiated thyroid cancer: an American Head and Neck Society consensus statement.AHNS consensus statement[J].Head Neck,2014,36(10):1379-1390.
[53] Stack B J, Bimston D N, Bodenner D L, et al.American Association of Clinical Endocrinologists and American College of Endocrinology Disease state clinical review:Postoperative hypoparathyroidism-definitions and management [J].Endocr Pract, 2015, 21(6):674-685.
[54] Pacini F, Castagna M G, Brilli L, et al.Thyroid cancer:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up[J].Ann Oncol,2012,23 Suppl 7:i110-i119.